Atsena Therapeutics
Durham, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $150M
Overview
A clinical-stage gene therapy company developing sight-saving treatments for inherited retinal diseases.
OphthalmologyGenetics & Genomics
Technology Platform
A proprietary AAV-based gene therapy platform featuring novel vector designs and subretinal delivery techniques optimized for targeting photoreceptor cells in the retina.
Funding History
1Total raised:$150M
Venture$150M
Opportunities
Potential to address multiple monogenic retinal diseases with its adaptable platform, leading to a pipeline of high-value, one-time therapies.
Risk Factors
Clinical risk associated with novel delivery methods and the potential for immune responses that could limit efficacy or durability.
Competitive Landscape
Operates in a competitive gene therapy ophthalmology space, requiring differentiation through its delivery technology and clinical data in specific genetic subtypes.